Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Sustainability & Impact
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
  • Support
    • Our Value Creation Approach
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products

Global private equity healthcare specialist ARCHIMED announces the acquisition of DermaPharm A/V. DermaPharm is a leading player in Nordic suncare and a world-renowned skincare contract development & manufacturing organization for third parties.

 

ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products

ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera

 November

 17, 

2023

ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita

 October

 27, 

2023

ARCHIMED Publishes White Paper – “Navigating the FHIR Landscape: A Strategic Approach for Healthcare IT Businesses”

 September

 27, 

2023

ARCHIMED raises €3.5 billion for MED Platform II, a record for a buyout fund exclusively investing in healthcare industries

 June

 5, 

2023

ARCHIMED’s sale of Polyplus to Sartorius Stedim earns 300x for MED I, an all-time record return for a private equity investment

 April

 13, 

2023

ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services

 March

 27, 

2023

< 1 2 3 4 5 6 … 16 >
368
  • ARCHIMED © 2025
  • Our Eco-Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
  • Manage your cookies
  • .
    Go top

    Back to top